Scott J Rodig
Inventor
Stats
- 2 US patents issued
- 12 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 2 US Patents Issued
- 12 US Applications Filed
- 106 Total Citation Count
- Oct 7, 2020 Most Recent Filing
- Nov 12, 2010 Earliest Filing
Work History
| Patent Owner | Applications Filed | Year |
|---|---|---|
| Consejo Nacional de Investigaciones Científicas y Técnicas | 1
| 2015
|
| DANA-FARBER CANCER INSTITUTE, INC. | 2
2 1 2 | 2010
2013 2014 2015 |
| THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 1
2 | 2010
2015 |
| CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET) | 1
| 2010
|
| Consejo Nacional De Investigaciones Cientificias Y Tecnicas | 1
| 2015
|
| Consejo Nactional De Investigaciones Cientificias Y Tecnicas | 2
| 2010
|
| THE BROAD INSTITUTE, INC. | 2
| 2013
|
| FUNDACION SALES | 1
1 | 2010
2015 |
Inventor Addresses
| Address | Duration |
|---|---|
| Westwood, MA, US | Jan 10, 13 - Aug 15, 23 |
Technology Profile
| Technology | Matters | |
|---|---|---|
| A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 11 |
| A61P: | THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS | 1 |
| C07K: | PEPTIDES | 10 |
Patents / Publication
| Patents / Publication # | Year of Publication / Issued | Title | Citations |
|---|---|---|---|
| 11723972 | 2023 | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 | 0 |
| 11673956 | 2023 | Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutralizing Gal1 | 0 |
| 2021/0095,035 | 2021 | ANTI-GALECTIN-1 (GAL1) MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF FOR NEUTRALIZING GAL1 | 0 |
| 10948492 | 2021 | PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers | 0 |
| 10844126 | 2020 | Anti-galectin-1 (GAL1) monoclonal antibodies and fragments thereof for neutralizing GAL1 | 1 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.